About Us

Learn about hepatitis C, the State of Medicaid Access Report and its authors.

Background

About hepatitis C and treatment access restrictions.

What is Hepatitis C?

Hepatitis C is the deadliest infectious disease in the U.S., affecting approximately 3.5 million Americans, according to the Centers for Disease Control and Prevention, and many of these are Medicaid recipients.

Some state Medicaid programs are restricting access to cures for the virus, which kills more Americans each year than all other infectious diseases, including HIV, combined.

Effective treatment exists

For the past several decades, hepatitis C treatment has revolved around painful interferon injections, which are vastly ineffective at managing the epidemic on an individual and public health level. In 2013, curative treatments known as direct acting antiviral agents (DAAs) were introduced to combat hepatitis C – offering cure rates of near 100 percent with minimal side effects.

These curative treatments offer hepatitis C patients an unprecedented chance to live virus-free – and avoid liver failure, cancer-causing cirrhosis, liver transplants, and other costly health complications.

Access to treatment is limited

Unfortunately, despite the important individual and public health potential of these cures, many state Medicaid programs have limited access to hepatitis C treatments due to cost concerns. These Medicaid coverage restrictions include:

  • Liver Disease Progression: Requiring that patients reach a certain stage of fibrosis (liver disease), which can be irreversible and cause cancer;
  • Substance Use/Sobriety Requirements: Barring patients with a history of substance or alcohol abuse;
  • Prescriber Restrictions: Only allowing certain specialists, who are not readily available, to prescribe a cure.

Fatal Consequences

By limiting the safest and most effective treatments only to patients who satisfy a certain set of requirements, state Medicaid programs have imposed significant barriers to care for millions of Americans enrolled in Medicaid, despite clear guidance from the Centers for Medicare and Medicaid Services (CMS) that such restrictions often violate federal law.

These restrictions also directly oppose treatment recommendations issued by two of the leading medical authorities on hepatitis C, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA).

The Project

Hepatitis C: State of Medicaid Access is the culmination of work by the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) to definitively assess the state of access to DAAs for Medicaid enrollees across America. Through a national report and state-by-state report cards, the project provides an in-depth evaluation of DAA access in each state’s Medicaid program, while highlighting successes in access expansion as well as ongoing challenges.

The Most Significant Restrictions to Treatment:

Liver Damage Restrictions

Liver damage or disease progression.

Sobriety Restrictions

Periods of abstinence from substance or alcohol use prior to treatment.

Prescriber Restrictions

Designating which health care providers can prescribe treatment.

The Authors

National Viral Hepatitis Roundtable (NVHR)

The National Viral Hepatitis Roundtable (NVHR) is a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics. We seek an aggressive response from policymakers, public health officials, medical and health care providers, the media, and the general public through our advocacy, education, and technical assistance. NVHR believes an end to the hepatitis B and C epidemics is within our reach and can be achieved through addressing stigma and health disparities, removing barriers to prevention, care and treatment, and ensuring respect and compassion for all affected communities.

Center for Health Law and Policy Innovation of Harvard Law School (CHLPI)

The Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) advocates for legal, regulatory, and policy reforms to improve the health of underserved populations, with a focus on the needs of low-income people living with chronic illnesses and disabilities. CHLPI works with consumers, advocates, community-based organizations, health and social services professionals, government officials, and others to expand access to high-quality healthcare; to reduce health disparities; to develop community advocacy capacity; and to promote more equitable and effective healthcare systems. CHLPI is a clinical teaching program of Harvard Law School and mentors students to become skilled, innovative, and thoughtful practitioners as well as leaders in health and public health law and policy.